论文部分内容阅读
目的:探讨晚期膀胱癌患者血清CA19-9检测的临床意义。方法:采用电化学发光法测定41例晚期膀胱癌患者外周血CA19-9水平,并对其临床意义进行分析。结果:本组患者CA19-9测定值为(77.1±194.3)IU/ml,其中CA19-9阳性19例,阳性率为46.3%;对照组CA19-9测定值为(13.6±5.2)IU/ml,阳性率为0,两组相比差异有显著统计学意义(P<0.01)。病理检查证实淋巴结转移的11例患者CA19-9阳性率为54.5%,阴性组为14.2%,两组相比差异有统计学意义(P<0.05)。6例远处器官转移的患者中有5例CA19-9阳性,阳性率为83.3%,与无远处转移的患者相比,阳性率差异有统计学意义(P<0.05)。41例患者随访3～46个月,CA19-9阳性组、阴性组3年生存率分别为52.1%和85.9%,差异有统计学意义(P=0.036).036)。结论:血清CA19-9水平与肿瘤的进展以及预后密切相关,可能是判断晚期膀胱癌生物学行为的一项有用的指标。
Objective: To investigate the clinical significance of serum CA19-9 in patients with advanced bladder cancer. Methods: The levels of CA19-9 in peripheral blood of 41 patients with advanced bladder cancer were determined by electrochemiluminescence method and their clinical significance was analyzed. Results: The measured value of CA19-9 in this group was (77.1 ± 194.3) IU / ml, of which 19 were positive for CA19-9, the positive rate was 46.3%. The control group had a value of (13.6 ± 5.2) IU / ml , The positive rate was 0, the difference between the two groups was statistically significant (P <0.01). The positive rate of CA19-9 in 11 patients with lymph node metastasis confirmed by pathology was 54.5% and that in the negative group was 14.2%. There was significant difference between the two groups (P <0.05). Among 6 patients with distant organ metastases, 5 were positive for CA19-9, with a positive rate of 83.3%. There was a significant difference in the positive rate of patients with distant metastasis (P <0.05). The 41 patients were followed up for 3 to 46 months. The 3-year survival rates of CA19-9 positive group and negative group were 52.1% and 85.9%, respectively, with significant difference (P = 0.036). Conclusion: Serum CA19-9 level is closely related to tumor progression and prognosis, which may be a useful indicator to judge the biological behavior of advanced bladder cancer.